Guidelines for anti-emetic therapy: acute emesis

This publication has 65 references indexed in Scilit:

• Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
  Journal of Clinical Oncology, 1998
• Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center.
  Journal of Clinical Oncology, 1998
• Recommended breast cancer surveillance guidelines. American Society of Clinical Oncology.
  Journal of Clinical Oncology, 1997
• A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy
  Supportive Care in Cancer, 1997
• Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy
  European Journal Of Cancer, 1996
• Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group.
  Journal of Clinical Oncology, 1995
• Ondansetron Compared with Granisetron in the Prophylaxis of Cisplatin-lnduced Acute Emesis: A Multicentre Double-Blind, Randomised, Parallel-Group Study
  Oncology, 1994
• Ondansetron
  Drugs, 1993
• The impact of cytotoxic chemotherapy - perspectives from patients, specialists and nurses
  European Journal Of Cancer, 1992
• On the receiving end—patient perception of the side-effects of cancer chemotherapy
  European Journal of Cancer and Clinical Oncology, 1983